Affordable Access

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Authors
  • Pritchard, Jon
  • Cotterill, Simon J
  • Germond, Shirley M
  • Imeson, John
  • de Kraker, Jan
  • Jones, David R
Type
Published Article
Journal
Pediatric blood & cancer
Publication Date
Apr 01, 2005
Volume
44
Issue
4
Pages
348–357
Identifiers
PMID: 15546135
Source
Medline
License
Unknown

Abstract

In this trial, high dose melphalan improved the length of EFS and overall survival of children with stage IV neuroblastoma >1 year of age who achieved CR or GPR after OPEC induction therapy and surgery. Multi-agent myeloablative regimens are now widely used as consolidation therapy for children with stage IV disease and in those with other disease stages when the MYCN gene copy number in tumour cells is amplified. Because they are more toxic, complex, and costly these combination megatherapy regimens should be compared with single agent melphalan in randomised clinical trials.

Report this publication

Statistics

Seen <100 times